[{"orgOrder":0,"company":"Alfasigma","sponsor":"Poseidon CRO","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Poseidon CRO","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Poseidon CRO"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Dermatology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Dermatology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Biorasi"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Cromsource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Immunology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Cromsource","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Cromsource"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Parexel"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Alfasigma","amount2":0.79000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"||Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Alfasigma","amount2":0.79000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Piperaquine Tetraphosphate","moa":"Plasmodium falciparum","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"Alfasigma","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alfasigma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alfasigma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Avidinox","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Avidinox","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PMF104","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Clinedem","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alfasigma \/ Clinedem","highestDevelopmentStatusID":"9","companyTruncated":"Alfasigma \/ Clinedem"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Alfredo Di Leo","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Nephrology","graph2":"Phase IV","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Alfredo Di Leo","highestDevelopmentStatusID":"11","companyTruncated":"Alfasigma \/ Alfredo Di Leo"},{"orgOrder":0,"company":"Alfasigma","sponsor":"UMC Utrecht","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ UMC Utrecht","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ UMC Utrecht"}]
Find Clinical Drug Pipeline Developments & Deals by Alfasigma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
